13F reference period
Q2 2026
Security Snapshot
Definium Therapeutics, Inc. - Common Shares, no par value per share (DFTX) Institutional Ownership
CUSIP: 24477V105
13F Institutional Holders and Ownership History from Q4 2025 to Q3 2026
Institutions Reporting
359
Shares (Excl. Options)
113.02M
Full value: 113,021,246 · shares · 30 Jun 2026Price
$47.04
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, no par value per share
- Symbol
- DFTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 113,021,246
- Total 13F value
- $5,315,978,710
- Portfolio coverage rank
- 0.01%
- Share change
- +32,947,333
- Value change
- +$1,639,427,089
- Number of holders
- 359
- Shares outstanding
- 133,888,889
- SEC-reported price per share
- $34.38
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- DFTX - Definium Therapeutics, Inc. - Common Shares, no par value per share is tracked under CUSIP 24477V105.
- 359 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 245 to 359 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$1.47B
Full value: $1,474,465,726 · USD · 31 Mar 2026.$5.32B
Full value: $5,315,978,710 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 359 institutions filings for Q2 2026.
Security key
24477V105
13F reference period
Q2 2026
13F holders
359
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
DFTX full holder history
Definium Therapeutics, Inc. SEC filings
Definium Therapeutics, Inc. company facts
Definium Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 24477V105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
DFTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| DRIEHAUS CAPITAL MANAGEMENT LLC | 5.4% | -18% | $298,796,297 | +$13,447,430 | 6,845,276 | +4.7% | DRIEHAUS CAPITAL MANAGEMENT LLC | 30 Jun 2026 |
| Avoro Capital Advisors LLC | 5.1% | 5,000,000 | Avoro Capital Advisors LLC | 31 Dec 2025 | ||||
| Deep Track Capital, LP | 3% | -42% | $66,750,000 | -$59,553,015 | 3,000,000 | -47% | Deep Track Capital, LP | 31 Mar 2026 |
| Commodore Capital LP | 1.8% | -77% | $105,196,500 | -$219,069,529 | 2,410,000 | -68% | Commodore Capital LP | 30 Jun 2026 |
As of 30 Jun 2026,
359
institutional investors reported holding
shares of
Definium Therapeutics, Inc. - Common Shares, no par value per share (DFTX).
This represents
84%
of the company’s total
outstanding shares.
113.02M
Full value: 113,021,246 · shares · 30 Jun 2026133.89M
Full value: 133,888,889 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
61%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.4% | 11,232,834 | +32% | 0.01% | $528,392,511 |
| Avoro Capital Advisors LLC | 5.4% | 7,188,888 | +44% | 3% | $338,165,292 |
| Driehaus Capital Management LLC | 5.1% | 6,845,276 | +16% | 1.9% | $322,001,783 |
| Jupiter Topco LLC | 4.2% | 5,615,645 | 0% | 0.11% | $264,002,611 |
| Capital World Investors | 4% | 5,367,723 | 0.03% | $252,497,690 | |
| FMR LLC | 3.5% | 4,752,921 | +163% | 0.01% | $223,577,402 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.5% | 4,652,032 | +6546% | 0.02% | $218,833,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.7% | 3,644,813 | +46% | 0.01% | $171,482,802 |
| STATE STREET CORP | 2.3% | 3,065,390 | +24% | 0% | $144,195,946 |
| Capital International Investors | 2.2% | 2,963,410 | 0.03% | $139,398,806 | |
| Octagon Capital Advisors LP | 2.2% | 2,950,000 | +21% | 13% | $138,768,000 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.2% | 2,949,734 | +126% | 0.02% | $138,755,487 |
| Deep Track Capital, LP | 2.1% | 2,750,000 | -8.3% | 1.9% | $129,360,000 |
| Commodore Capital LP | 1.5% | 2,000,000 | 0% | 5.6% | $94,080,000 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,800,852 | +7.5% | 0.01% | $84,712,079 |
| CITADEL ADVISORS LLC | 1.3% | 1,688,587 | +27% | 0.05% | $79,431,133 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.2% | 1,648,426 | +89% | 0% | $77,541,959 |
| RA CAPITAL MANAGEMENT, L.P. | 1.1% | 1,500,000 | 0.61% | $70,560,000 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.1% | 1,486,454 | +36% | 0% | $69,922,796 |
| Siren, L.L.C. | 1.1% | 1,419,493 | +54% | 1.4% | $66,772,951 |
| MARSHALL WACE, LLP | 0.97% | 1,298,946 | +8.2% | 0.05% | $61,102,420 |
| NORTHERN TRUST CORP | 0.87% | 1,169,238 | +46% | 0.01% | $55,000,956 |
| AMERIPRISE FINANCIAL INC | 0.86% | 1,148,363 | +19% | 0.01% | $54,018,997 |
| Nuveen, LLC | 0.83% | 1,105,314 | +58% | 0.01% | $51,993,971 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.81% | 1,083,576 | +34% | 0.01% | $50,971,415 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Headline period
Q2 2026
Rows shown
1-4 of 4
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,125,064 | $42,672,634 | +$3,975,417 | $38.06 | 67 |
| 2026 Q2 | 113,021,246 | $5,315,978,710 | +$1,639,427,089 | $47.04 | 359 |
| 2026 Q1 | 78,037,591 | $1,474,465,726 | +$1,211,085,775 | $18.90 | 245 |
| 2025 Q4 | 11,252,538 | $150,679,840 | +$150,673,017 | $13.39 | 8 |